ZBH vs. ALGN, SNN, EW, CAH, ICLR, RMD, ARGX, BIIB, WST, and MOH
Should you be buying Zimmer Biomet stock or one of its competitors? The main competitors of Zimmer Biomet include Align Technology (ALGN), Smith & Nephew (SNN), Edwards Lifesciences (EW), Cardinal Health (CAH), ICON Public (ICLR), ResMed (RMD), argenx (ARGX), Biogen (BIIB), West Pharmaceutical Services (WST), and Molina Healthcare (MOH). These companies are all part of the "medical" sector.
Zimmer Biomet (NYSE:ZBH) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability.
Zimmer Biomet has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
Zimmer Biomet received 124 more outperform votes than Align Technology when rated by MarketBeat users. However, 69.64% of users gave Align Technology an outperform vote while only 68.36% of users gave Zimmer Biomet an outperform vote.
Zimmer Biomet has a net margin of 13.85% compared to Align Technology's net margin of 11.80%. Align Technology's return on equity of 14.22% beat Zimmer Biomet's return on equity.
Zimmer Biomet has higher revenue and earnings than Align Technology. Zimmer Biomet is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Align Technology had 16 more articles in the media than Zimmer Biomet. MarketBeat recorded 35 mentions for Align Technology and 19 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.02 beat Align Technology's score of 0.46 indicating that Zimmer Biomet is being referred to more favorably in the media.
88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 88.4% of Align Technology shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by insiders. Comparatively, 0.6% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Zimmer Biomet presently has a consensus target price of $139.39, indicating a potential upside of 16.79%. Align Technology has a consensus target price of $353.00, indicating a potential upside of 14.23%. Given Zimmer Biomet's higher probable upside, equities analysts plainly believe Zimmer Biomet is more favorable than Align Technology.
Summary
Align Technology beats Zimmer Biomet on 10 of the 18 factors compared between the two stocks.
Get Zimmer Biomet News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zimmer Biomet Competitors List
Related Companies and Tools
